中文名 | 雷马曲班 |
英文名 | Ramatroban |
别名 | 雷马曲斑 雷马曲班 3R-(4-氟苯磺酰氨基)-1,2,3,4-四氢化-9H-咔唑-9-丙酸 3R-[[(4-氟苯基)磺酰]氨基]-1,2,3,4-四氢-9H-咔唑-9-丙 酸 (R)-3-(3-(4-氟苯基磺酰胺基)-3,4-二氢-1H-咔唑-9(2H)-基)丙酸 |
英文别名 | CS-1350 BAY-U3405 BAY U3405 Ramatroban BAY-U3405 (R)-3-(3-(4-fluorophenylsulfonamido)-3,4-dihydro-1H-carbazol-9(2H)-yl)propanoic acid 3R-[[(4-FLUOROPHENYL)SULFONYL]AMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-PROPANOIC ACID 3-(1,2,3,4-tetrahydrocarbazol-9-yl)propanoic acid [(4-fluorophenyl)sulfonylamino] ester 3R-[[(4-Fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-. carbazole-9-propanoic acid (3R)-3-[[(4-Fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propionic acid 3-[(3R)-3-(4-Fluorophenylsulfonylamino)-1,2,3,4-tetrahydro-9H-carbazole-9-yl]propionic acid 3-[(3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl]propanoic acid |
CAS | 116649-85-5 |
化学式 | C21H21FN2O4S |
分子量 | 416.47 |
InChI | InChI=1/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1 |
密度 | 1.43±0.1 g/cm3(Predicted) |
熔点 | 134-135° |
沸点 | 654.7±65.0 °C(Predicted) |
比旋光度 | D +70.1° (c = 1.0 in methanol) |
闪点 | 349.7°C |
蒸汽压 | 4.94E-18mmHg at 25°C |
溶解度 | DMSO: ≥ 40 mg/mL |
折射率 | 1.664 |
酸度系数 | 4.60±0.10(Predicted) |
存储条件 | Sealed in dry,2-8°C |
外观 | 固体 |
颜色 | white |
体外研究 | Ramatroban is a potent human thromboxane receptor (hTP) antagonist with an IC 50 of 18 nM in a human TP binding assay. Ramatroban inhibits prostaglandin D 2 receptor DP2 (CRTH2) with an IC 50 of 113 nM in a human DP2 binding assay. Ramatroban also inhibits human CYP isoform CYP2C9 with an IC 50 of 15 μM. Ramatroban is a selective thromboxane-type prostanoid (TP) receptor antagonist. PGD 2 -stimulated human eosinophil migration is shown to be mediated exclusively through activation of CRTH2, and surprisingly, these effects are completely inhibited by Ramatroban. Ramatroban is an antagonist for CRTH2, and inhibits PGD 2 -induced migration of eosinophils via CRTH2 blockade. 3 H-labeled PGD 2 binds to a single site on CRTH2 transfectants with high affinity (K D =6.3 nM, B max =450 pM). Nonlabeled PGD 2 inhibits the binding of 3 H-labeled PGD 2 to CRTH2 transfectants in a concentration-dependent manner with an EC 50 value of 2.7 nM. Ramatroban shows significant inhibitory effects on the binding of 3 H-labeled PGD 2 to CRTH2, albeit with much lower potency (IC 50 =100 nM). Ramatroban also inhibits PGD 2 -induced Ca 2+ mobilization in CRTH2 transfectants to almost the same extent with an IC 50 value of 30 nM. Ramatroban completely inhibits the PGD 2 -induced migration of eosinophils in a concentration-dependent manner with an IC 50 value of 170 nM. |
体内研究 | Ramatroban is an orally bioavailable small molecule antagonist of CRTH2. Systemic administration of Ramatroban (30 mg/kg) in CRTH2 +/+ mice produces the same effects as seen in CRTH2 deficiency. Ramatroban completely blocks LPS-induced decreases in social and object exploratory behavior (p<0.01). In addition, tumor-impaired social interaction and object exploratory behavior in CRTH2 +/+ mice are completely reversed by a single injection of Ramatroban, even when the tumor is enlarged. |
危险品标志 | Xi - 刺激性物品 |
风险术语 | 36/37/38 - 刺激眼睛、呼吸系统和皮肤。 |
安全术语 | S26 - 不慎与眼睛接触后,请立即用大量清水冲洗并征求医生意见。 S36/37/39 - 穿戴适当的防护服、手套和护目镜或面具。 S45 - 若发生事故或感不适,立即就医(可能的话,出示其标签)。 |
WGK Germany | 1 |
上游原料 | 1,2,4,9-四氢咔唑-3-酮 (R)-3-氨基-1,2,3,4-四氢咔唑 1,4-环己二酮单乙二醇缩酮 苯肼 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.401 ml | 12.006 ml | 24.012 ml |
5 mM | 0.48 ml | 2.401 ml | 4.802 ml |
10 mM | 0.24 ml | 1.201 ml | 2.401 ml |
5 mM | 0.048 ml | 0.24 ml | 0.48 ml |